Predictive factors for long-term survival after a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; ReoPro(R)) in patients undergoing high-risk percutaneous coronary intervention in acute myocardial infarction.
- Author:
Weon KIM
1
;
Eun A CHUNG
;
Myung Ho JEONG
;
Ji Hyun LIM
;
Han Gyun KIM
;
Hyung Wook PARK
;
Young Joon HONG
;
Ok Young PARK
;
Ju Han KIM
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Platelets;
Receptor;
Myocardial Infarction;
Angioplasty
- MeSH:
Angioplasty;
Arteries;
Blood Platelets*;
Follow-Up Studies;
Glycoproteins*;
Hemorrhage;
Humans;
Incidence;
Jeollanam-do;
Logistic Models;
Myocardial Infarction*;
Percutaneous Coronary Intervention*;
Prevalence
- From:Korean Journal of Medicine
2003;65(3):289-299
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: High-risk percutaneous coronary interventions (PCI) are associated with high complication rate, low procedural success rate and high restenosis rate. we analyzed the predictive factors of major adverse cardiac events (MACE) after administration a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; Reo-Pro(R)) in Korean patients with acute myocardial infarction (AMI) underwent high-risk PCI. METHODS: One hundred twenty-seven AMI patients with 158 lesion sites were administered ReoPro(R) who underwent high-risk PCI out of 3,532 patients at Chonnam National University Hospital between March 1999 and December 2001. The patients were divided into two groups: 94 patients without major adverse cardiac event (MACE) (Group I, 60.0 +/- 10.2 years, 73 male), and 33 patients with MACE (Group II, 59.8 +/- 9.7 years, 26 male) during clinical follow-up of 25.2 +/- 10.4 months duration. RESULTS: The primary success rate was 91.3% (116/127). Clinical follow-up was performed in 97.6% of patients. The MACE were developed in 33 cases (26.0%) composed of 8 deaths (6.3%) and 5 AMI (3.9%). There was no major bleeding after PCI. Prevalence of diabetes, target lesion artery, ACC/AHA types and inflammatory marker were not different between the two groups. The predictive factors of MACE by multiple logistic regression analysis were incidence of multi-vessel disease and Thrombolysis In Myocardial Infarction (TIMI) flow grade 0-1 after PCI in group II than in group I (p=0.036, 0.033, respectively). CONCLUSION: Multi-vessel lesion and low TIMI flow after high-risk PCI were associated with MACE in AMI patients treated on ReoPro(R) during long-term clinical follow-up.
